BPC-157 vs Thymosin Alpha-1
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It has been extensively studied in animal models for tissue repair, gastroprotection, and tendon/ligament/muscle healing. Important: essentially all efficacy data are preclinical (rodent), there are no completed published human efficacy trials, and it is prohibited in sport by WADA.
Full profileThymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally derived from the thymus gland. It plays a central role in regulating immune function — specifically in the maturation and differentiation of T-cells. Unlike most research peptides, Thymosin Alpha-1 has approved clinical use in multiple countries (China, Italy, and others) for hepatitis B, hepatitis C, and as an immune adjuvant in cancer patients undergoing chemotherapy. In the US it is sold as Zadaxin and used as a research compound.
Full profile| BPC-157 | Thymosin Alpha-1 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Body Protection Compound 157, PL 14736, Pentadecapeptide BPC 157 | Tα1, Thymalfasin, Zadaxin |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 200mcg–1000mcg mcg, once or twice daily | 900mcg–3.2mg mg, 2–3 times per week subcutaneously |
| Administration | Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols) | Subcutaneous injection |
| Key side effects | Nausea (rare, typically at higher doses), Dizziness / lightheadedness shortly after injection (uncommon, anecdotal), Injection site redness or irritation, Human safety profile is not established — no controlled human trials | Generally very well tolerated, Mild injection site reactions (most common), Transient fatigue in initial doses, Flu-like symptoms (rare) |
| Cited sources | 6 references | 4 references |
Key differences
- Evidence level differs: BPC-157 is preclinical only, while Thymosin Alpha-1 is research-stage.
- Administration: BPC-157 — Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols); Thymosin Alpha-1 — Subcutaneous injection.
- Dosing units differ: BPC-157 is dosed in mcg, Thymosin Alpha-1 in mg — they operate at different scales.
- Frequency: BPC-157 is typically once or twice daily; Thymosin Alpha-1 is 2–3 times per week subcutaneously.
- Research depth: this profile cites 6 sources for BPC-157 vs 4 for Thymosin Alpha-1.
How each works
BPC-157
Preclinical rodent and in-vitro studies — predominantly from the Sikiric group in Zagreb, with mechanistic angiogenesis work from Pang's group in Taiwan — report accelerated healing of tendon, ligament, muscle, and gut tissue. Proposed mechanisms include modulation of the nitric oxide (NO) system, promotion of angiogenesis via the VEGFR2–Akt–eNOS pathway, upregulation of growth factor signaling, and effects along the gut–brain axis. Despite a large and internally consistent animal literature, BPC-157 has no completed human clinical efficacy trials and is an unapproved drug.
Thymosin Alpha-1
Extensive human clinical research documents Tα1's immune-modulating effects. It increases T-cell counts, enhances NK cell activity, and promotes Th1 cytokine balance. Multiple randomized trials have shown efficacy in treating chronic hepatitis B and C, reducing infection severity in critically ill patients, and improving outcomes in sepsis. More recent research investigates its role in long COVID immune dysregulation. It is considered one of the best-studied peptides in immunology.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.